> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Insmed Says It Won't Build A Traditional European Sales Operation For BRINSUPRI
- URL: https://www.bullished.co/insmed-says-it-wont-build-a-traditional-european-sales-operation-for-brinsupri-7bd53000/
- Published: 2026-10-29T11:37:00.000Z
- Updated: 2026-10-29T11:37:00.000Z
- Description: The drugmaker cites tight European healthcare funding and shifting US policy, and flags a pending $35.0 million AstraZeneca milestone.
- Author: Matteo Parrino
- Tags: SEC Filings, INSM, Industry: Healthcare

[Insmed](https://www.bullished.co/tag/insm/), the biopharmaceutical company behind the lung drugs ARIKAYCE and BRINSUPRI, has ruled out a conventional European commercial setup "for the foreseeable future," according to its [quarterly report](https://www.sec.gov/Archives/edgar/data/0001104506/000110450626000047/insm-20260930.htm?ref=bullished.co) filed Thursday. The company blames a challenging healthcare funding environment in Europe and evolving US policies.

## A changed explanation for Europe

The [prior quarter's filing](https://www.sec.gov/Archives/edgar/data/0001104506/000110450626000041/insm-20260630.htm?ref=bullished.co) said Insmed was still weighing the effect of evolving US policies, which would shape the timing of future international launches. That sentence is gone, replaced by the European retreat. The filing adds that there are "certain other pathways available for patients to receive treatment."

In Europe, BRINSUPRI revenue comes from early access programs, which the filing now says run mostly via named patient programs in some countries. International BRINSUPRI sales were $2.0 million in the third quarter, against $398.1 million in the US.

The company's priorities now include a Japan launch. Japan's health ministry approved BRINSUPRI in August, and Insmed says it launched the tablet there in October.

## A $35.0 million AstraZeneca payment turns probable

As of September 30, Insmed judged it probable that BRINSUPRI will reach $1.0 billion in net sales in a calendar year. That triggers a pending $35.0 million milestone payable to AstraZeneca, booked as a liability and an intangible asset.

Amortization of the AstraZeneca-related assets is now estimated at $12.0 million a year for 2027 through 2029, up from $8.3 million in the prior filing's estimate. Separately, a $15.0 million milestone became payable in August after Japan's approval.

The filing is a [10-Q](https://www.sec.gov/Archives/edgar/data/0001104506/000110450626000047/insm-20260930.htm?ref=bullished.co), the quarterly report public companies file.

## BRINSUPRI drives a 268% revenue jump

Insmed's [earnings release](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-1.htm?ref=bullished.co) put third-quarter revenue at $524.4 million, up 268% from $142.3 million a year earlier. BRINSUPRI contributed $400.1 million and ARIKAYCE $124.4 million. The net loss narrowed to $100.3 million from $370.0 million.

The company raised its 2026 BRINSUPRI revenue guidance to $1.35 billion to $1.4 billion, from $1.25 billion to $1.4 billion. ARIKAYCE guidance now stands at $460 million to $470 million, from $450 million to $470 million. Insmed had about $1.1 billion in cash and marketable securities at quarter's end.

The FDA's target action date for Insmed's ARIKAYCE supplemental application is January 28, 2027.

### Sources

- [10-Q Filing — Insmed (INSM)](https://www.sec.gov/Archives/edgar/data/0001104506/000110450626000047/insm-20260930.htm?ref=bullished.co) — SEC EDGAR
- [10-Q Filing — Insmed (INSM), Q2 FY2026 filed 2026-08-06 (comparison basis)](https://www.sec.gov/Archives/edgar/data/0001104506/000110450626000041/insm-20260630.htm?ref=bullished.co) — SEC EDGAR
- [Earnings release (8-K Item 2.02, ef20084500\_ex99-1.htm) — Insmed, filed 2026-10-29](https://www.sec.gov/Archives/edgar/data/0001104506/000114036126041097/ef20084500%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Insmed: Q3 Earnings Snapshot | 9news.com](https://www.9news.com/article/syndication/associatedpress/insmed-q3-earnings-snapshot/616-22889df9-7f42-43f1-af64-05544a5e9a49?ref=bullished.co) — Associated Press
- [Insmed: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/insmed-q3-earnings-snapshot/616-22889df9-7f42-43f1-af64-05544a5e9a49?ref=bullished.co) — Associated Press
- [Insmed: Q3 Earnings Snapshot | khou.com](https://www.khou.com/article/syndication/associatedpress/insmed-q3-earnings-snapshot/616-22889df9-7f42-43f1-af64-05544a5e9a49?ref=bullished.co) — Associated Press
- [Insmed: Q3 Earnings Snapshot | king5.com](https://www.king5.com/article/syndication/associatedpress/insmed-q3-earnings-snapshot/616-22889df9-7f42-43f1-af64-05544a5e9a49?ref=bullished.co) — Associated Press
- [HOEY v. INSMED INCORPORATED et al](https://www.law360.com/cases/578947ab96d5e863e9000002/articles?ref=bullished.co) — law360.com

### More on Insmed

- [Insmed Names Ex-Sanofi CEO Paul Hudson And Verily Health CFO Utpal Koppikar To Its Board](https://www.bullished.co/insmed-names-ex-sanofi-ceo-paul-hudson-and-verily-health-cfo-utpal-koppikar-to-its-board-26c095be/)
- [Insmed CFO Sara Bonstein To Leave October 30, Staying Through The Earnings Call](https://www.bullished.co/insmed-cfo-sara-bonstein-to-leave-october-30-staying-through-the-earnings-call-d0f10ddb/)

[All Insmed (INSM) coverage →](https://www.bullished.co/tag/insm/)